Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial

Hdl Handle:
http://hdl.handle.net/10144/618678
Title:
Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial
Authors:
Wasunna, M; Njenga, S; Balasegaram, M; Alexander, N; Omollo, R; Edwards, T; Dorlo, TPC; Musa, B; Ali, MHS; Elamin, MY; Kirigi, G; Juma, R; Kip, AE; Schoone, GJ; Hailu, A; Olobo, J; Ellis, S; Kimutai, R; Wells, S; Khalil, EAG; Strub Wourgaft, N; Alves, F; Musa, A
Journal:
PLoS Neglected Tropical Diseases
Abstract:
SSG&PM over 17 days is recommended as first line treatment for visceral leishmaniasis in eastern Africa, but is painful and requires hospitalization. Combination regimens including AmBisome and miltefosine are safe and effective in India, but there are no published data from trials of combination therapies including these drugs from Africa.
Publisher:
Public Library of Science (PLoS)
Issue Date:
14-Sep-2016
URI:
http://hdl.handle.net/10144/618678
DOI:
10.1371/journal.pntd.0004880
PubMed ID:
27627654
Submitted date:
2016-09-21
Language:
en
ISSN:
1935-2735
Appears in Collections:
Leishmaniasis/Kala Azar

Full metadata record

DC FieldValue Language
dc.contributor.authorWasunna, Men
dc.contributor.authorNjenga, Sen
dc.contributor.authorBalasegaram, Men
dc.contributor.authorAlexander, Nen
dc.contributor.authorOmollo, Ren
dc.contributor.authorEdwards, Ten
dc.contributor.authorDorlo, TPCen
dc.contributor.authorMusa, Ben
dc.contributor.authorAli, MHSen
dc.contributor.authorElamin, MYen
dc.contributor.authorKirigi, Gen
dc.contributor.authorJuma, Ren
dc.contributor.authorKip, AEen
dc.contributor.authorSchoone, GJen
dc.contributor.authorHailu, Aen
dc.contributor.authorOlobo, Jen
dc.contributor.authorEllis, Sen
dc.contributor.authorKimutai, Ren
dc.contributor.authorWells, Sen
dc.contributor.authorKhalil, EAGen
dc.contributor.authorStrub Wourgaft, Nen
dc.contributor.authorAlves, Fen
dc.contributor.authorMusa, Aen
dc.date.accessioned2016-10-10T18:56:41Z-
dc.date.available2016-10-10T18:56:41Z-
dc.date.issued2016-09-14-
dc.date.submitted2016-09-21-
dc.identifier.citationEfficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial. 2016, 10 (9):e0004880 PLoS Negl Trop Disen
dc.identifier.issn1935-2735-
dc.identifier.pmid27627654-
dc.identifier.doi10.1371/journal.pntd.0004880-
dc.identifier.urihttp://hdl.handle.net/10144/618678-
dc.description.abstractSSG&PM over 17 days is recommended as first line treatment for visceral leishmaniasis in eastern Africa, but is painful and requires hospitalization. Combination regimens including AmBisome and miltefosine are safe and effective in India, but there are no published data from trials of combination therapies including these drugs from Africa.en
dc.language.isoenen
dc.publisherPublic Library of Science (PLoS)en
dc.rightsArchived with thanks to PLoS Neglected Tropical Diseasesen
dc.titleEfficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trialen
dc.identifier.journalPLoS Neglected Tropical Diseasesen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.